VTGNHealthcare · BiotechnologyThe 4 Wall Street analysts covering VistaGen Therapeutics, Inc. hold a median 12-month price target of $1 — +308.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores VistaGen Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own VistaGen Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on VTGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +308.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Dec 2025 | Jefferies | Downgrade | Hold | $15 → $0.90 |
| 17 Dec 2025 | Maxim Group | Downgrade | Hold | — |
| 17 Dec 2025 | William Blair | Downgrade | Market Perform | — |
| 7 Dec 2023 | Jefferies | Upgrade | Buy | — |
| 14 Nov 2023 | Stifel | Initiates | Buy | — |
| 5 Sept 2023 | Maxim Group | Maintains | Buy | — |
| 7 Aug 2023 | Maxim Group | Upgrade | Buy | — |
| 26 July 2022 | Maxim Group | Downgrade | Hold | — |
| 22 July 2022 | William Blair | Downgrade | Market Perform | — |
| 20 May 2021 | Baird | Initiates | Outperform | — |
| 18 Feb 2021 | Jefferies | Initiates | Buy | — |
| 4 Jan 2021 | William Blair | Upgrade | Outperform | — |
| 8 Oct 2020 | Aegis Capital | Initiates | Buy | — |
| 28 Aug 2019 | William Blair | Initiates | Outperform | — |
| 22 July 2019 | Chardan Capital | Downgrade | Neutral | $22 → $0.70 |
| 27 June 2018 | Maxim Group | Initiates | Buy | — |
| 24 May 2018 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 76% of US stocks
Cheaper than 17% of US stocks
Cheaper than 88% of US stocks
Cheaper than 59% of US stocks
Higher than 88% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VTGN appears on the weeks it earns a place.
Vistagen announced the appointment of Douglas J. Williamson to its Board of Directors. Williamson joins the board of the late clinical-stage biopharmaceutical company focused on intranasal neuroscience therapies.
Why it matters — A new board appointment may signal fresh strategic oversight as Vistagen advances its pherine-based intranasal product candidates through clinical development.
The 4 Wall Street analysts covering VistaGen Therapeutics, Inc. have a median 12-month price target of $1, with estimates ranging from $1 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering VistaGen Therapeutics, Inc., 0 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks VistaGen Therapeutics, Inc. 4 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, VistaGen Therapeutics, Inc. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +308.2% from the last close, and Ticker Nerd's factor model ranks VistaGen Therapeutics, Inc. 4 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering VistaGen Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $1 over the next 12 months.
VistaGen Therapeutics, Inc. returned -91.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
VistaGen Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for neuropsychiatric and neurological disorders using nose-to-brain neurocircuitry.
The most recent item we track (GlobeNewsWire, 31 July 2026): "Vistagen Appoints Douglas J. Williamson to its Board of Directors". Vistagen announced the appointment of Douglas J. Williamson to its Board of Directors. Williamson joins the board of the late clinical-stage biopharmaceutical company focused on intranasal neuroscience therapies.
VistaGen Therapeutics Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for neuropsychiatric and neurological disorders using nose-to-brain neurocircuitry. The company pioneers pherine-based nasal spray technologies, with its lead candidate Fasedienol in Phase III clinical trials for the acute treatment of anxiety in adults with social anxiety disorder. Another key investigational product, Itruvone, is advancing in Phase II trials for major depressive disorder. VistaGen Therapeutics Inc. also explores additional pipeline candidates like PH284 for cancer cachexia and AV-101 for neuropathic pain, targeting unmet needs in mental health and neurology. These odorless, synthetic neuroactive pherines aim to provide rapid, non-systemic interventions by directly modulating brain neurocircuits via the nasal pathway. Founded in 2008 and headquartered in South San Francisco, California, VistaGen Therapeutics Inc. plays a significant role in advancing neuroscience innovations for disorders affecting millions worldwide, emphasizing clinical advancement and strategic presentations at key industry conferences.
CEO Mr. Shawn K. Singh J.D. · 41 employees · United States · https://www.vistagen.com